



✓ 1614 \$

Docket No. MCP-264

#29  
JRP  
9/11/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Joseph R. Codispoti

Serial No. : 09/709,069

Art Unit: 1614

Filed : November 9, 2000

Examiner: D.A. Jagoe

For : METHOD FOR TREATING MIGRAINE SYMPTOMS WITH  
IBUPROFEN AND SALTS THEREOF

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

August 13, 2003  
(Date of Deposit)

Michele G. Mangini  
(Name of applicant, assignee, or Registered Representative)

*Michele G. Mangini*  
(Signature)

August 13, 2003  
(Date of Signature)

RECEIVED

AUG 19 2003

TECH CENTER 1600/2900

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

09709069

08/18/2003 STEUMEL1 00000049 100750

01 FC:1806 180.00 DA

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☒ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☒ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached); or

☒ Please charge Deposit Account No. 10-0750/MCP264/MGM the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the

national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

☒ Applicants wish to point out that an office action recently received in the related application, U.S.S.N. 09/706,681 (MCP 263), claims 1-14 were rejected under 35 USC §102(b) as being anticipated by the Diener, et al. publication and claims 1, 2, 5, 6, 9, and 11 were rejected under 35 U.S.C §102(b) as being anticipated by Goodman and Gilman, The Pharmacological Basis of Therapeutics (99<sup>th</sup> Ed. 1996) (copy attached). A copy of Diener was cited in the Information Disclosure Statement mailed in the above referenced application on November 9, 2000.


Please charge any deficiency or credit any overpayment to  
Deposit Account No. 10-0750/MCP264/MGM. This form is submitted  
in triplicate.

Respectfully submitted,



Michele G. Mangini  
Reg. No. 36,806  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2810  
DATED: August 13, 2003



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<i>Application Number</i>	09/709,069
<i>Filing Date</i>	November 9, 2000
<i>First Named Inventor</i>	J.R. Codispoti
<i>Group Art Unit</i>	1614
<i>Examiner Name</i>	D.A. Jagoe
<i>Attorney Docket Number</i>	MCP-264

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.